Stocks and Investing Stocks and Investing
Wed, March 11, 2020
Tue, March 10, 2020
Mon, March 9, 2020
Sun, March 8, 2020
Fri, March 6, 2020

Keay Nakae Upgraded (ABUS) to Strong Buy and Increased Target to $5 on, Mar 6th, 2020


Published on 2024-10-26 23:21:01 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Upgraded "Arbutus Biopharma Corporation" (ABUS) to Strong Buy and Increased Target from $1.5 to $5 on, Mar 6th, 2020.

Keay has made no other calls on ABUS in the last 4 months.



There are 2 other peers that have a rating on ABUS. Out of the 2 peers that are also analyzing ABUS, 0 agree with Keay's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Keay


  • Madhu Kumar of "Baird" Initiated at Buy and Held Target at $8 on, Thursday, February 20th, 2020
  • Liisa Bayko of "JMP Securities" Upgraded from Hold to Buy and Held Target at $10 on, Wednesday, February 5th, 2020